NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVRO shares have increased by 22.0% and is now trading at $134.00.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) posted its earnings results on Wednesday, August, 5th. The medical equipment provider reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.44. Nevro had a negative return on equity of 38.86% and a negative net margin of 27.22%.
View Nevro's earnings history.

10 brokerages have issued 12-month target prices for Nevro's shares. Their forecasts range from $100.00 to $165.00. On average, they anticipate Nevro's stock price to reach $140.40 in the next year. This suggests a possible upside of 4.8% from the stock's current price.
View analysts' price targets for Nevro.

Media stories about NVRO stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nevro earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Nevro.

Some companies that are related to Nevro include Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), Hill-Rom (HRC), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Irhythm Technologies (IRTC), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inari Medical (NARI), Inspire Medical Systems (INSP) and NuVasive (NUVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Adobe (ADBE), General Electric (GE), Incyte (INCY), Vertex Pharmaceuticals (VRTX) and ABIOMED (ABMD).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jackson Square Partners LLC (3.11%), Victory Capital Management Inc. (1.19%), Jennison Associates LLC (0.47%), Principal Financial Group Inc. (0.47%), Granite Investment Partners LLC (0.25%) and Swiss National Bank (0.20%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Mackay Shields LLC, SG Americas Securities LLC, HighTower Advisors LLC, Trexquant Investment LP, Mutual of America Capital Management LLC, State Board of Administration of Florida Retirement System, and Arizona State Retirement System. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Jennison Associates LLC, Granite Investment Partners LLC, Principal Financial Group Inc., Quantitative Systematic Strategies LLC, Foundry Partners LLC, Polianta Ltd, and Swiss National Bank. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $134.00.

Nevro has a market capitalization of $4.60 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]